Glaukos Corporation (GKOS): Price and Financial Metrics

Glaukos Corporation (GKOS): $96.50

1.37 (+1.44%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

C

GKOS Price/Volume Stats

Current price $96.50 52-week high $102.33
Prev. close $95.13 52-week low $45.38
Day low $94.16 Volume 697,810
Day high $98.70 Avg. volume 674,916
50-day MA $91.98 Dividend yield N/A
200-day MA $78.80 Market Cap 4.84B

GKOS Stock Price Chart Interactive Chart >


Glaukos Corporation (GKOS) Company Bio


Glaukos Corporation develops and commercializes products and procedures designed for the treatment of glaucoma. The company was founded in 1998 and is based in Laguna Hills, California.


GKOS Latest News Stream


Event/Time News Detail
Loading, please wait...

GKOS Latest Social Stream


Loading social stream, please wait...

View Full GKOS Social Stream

Latest GKOS News From Around the Web

Below are the latest news stories about GLAUKOS CORP that investors may wish to consider to help them evaluate GKOS as an investment opportunity.

Glaukos Corp President & COO Joseph Gilliam Sells 25,000 Shares

Joseph Gilliam, President & COO of Glaukos Corp (NYSE:GKOS), executed a sale of 25,000 shares in the company on December 21, 2023, according to a SEC Filing.

Yahoo | December 23, 2023

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

ALISO VIEJO, Calif., December 20, 2023--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 5:15 p.m. PT in San Francisco, CA.

Yahoo | December 20, 2023

Glaukos' (GKOS) iDose TR Gets FDA Nod for Glaucoma Treatment

The FDA approval of Glaukos' (GKOS) iDose TR is likely to reshape glaucoma care. A micro-invasive breakthrough promises proactive, durable treatment, heralding a new era in eye health.

Yahoo | December 19, 2023

Glaukos (GKOS) Hits 52-Week High: What's Aiding the Stock?

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Yahoo | December 18, 2023

Glaukos wins FDA approval for drug-releasing eye implant to treat glaucoma

William Blair analysts said the product “should revolutionize how glaucoma is treated by addressing noncompliance with drops.”

Yahoo | December 15, 2023

Read More 'GKOS' Stories Here

GKOS Price Returns

1-mo 10.55%
3-mo 5.71%
6-mo 42.35%
1-year 95.70%
3-year 11.46%
5-year 38.95%
YTD 21.40%
2023 81.98%
2022 -1.71%
2021 -40.95%
2020 38.17%
2019 -3.03%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!